ArriVent BioPharma (AVBP) Assets Average (2024 - 2026)

ArriVent BioPharma (AVBP) has 3 years of Assets Average data on file, last reported at $341.2 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 39.15% year-over-year to $341.2 million; the trailing twelve-month figure through Mar 2026 stood at $341.2 million (up 39.15% YoY), and the FY2025 full-year result was $304.1 million, up 38.83% from the prior year.
• Assets Average rose to $341.2 million in Q1 2026, from $329.9 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $341.2 million in Q1 2026 to a low of $242.5 million in Q2 2025.
• A 3-year average of $289.5 million and a median of $298.0 million in 2025 frame the typical range for Assets Average.
• Across the five-year window, Assets Average decreased 23.82% in 2025 and surged 39.15% in 2026, its largest moves.
• Tracing AVBP's Assets Average over 3 years: stood at $283.8 million in 2024, then climbed by 16.22% to $329.9 million in 2025, then gained by 3.45% to $341.2 million in 2026.
• Business Quant data shows AVBP's Assets Average at $341.2 million in Q1 2026, $329.9 million in Q4 2025, and $298.0 million in Q3 2025.